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Structure of full-length wild-type 
human phenylalanine hydroxylase 
by small angle X-ray scattering 
reveals substrate-induced 
conformational stability
catarina S. tomé  1,2, Raquel R. Lopes3, Pedro M. F. Sousa2, Mariana P. Amaro3,5, 
João Leandro3,5, Haydyn D. T. Mertens  4, Paula Leandro3 & João B. Vicente1
Human phenylalanine hydroxylase (hPAH) hydroxylates l-phenylalanine (l-Phe) to l-tyrosine, a 
precursor for neurotransmitter biosynthesis. Phenylketonuria (PKU), caused by mutations in PAH 
that impair PAH function, leads to neurological impairment when untreated. Understanding the hPAH 
structural and regulatory properties is essential to outline PKU pathophysiological mechanisms. 
Each hPAH monomer comprises an N-terminal regulatory, a central catalytic and a C-terminal 
oligomerisation domain. to maintain physiological l-Phe levels, hPAH employs complex regulatory 
mechanisms. Resting PAH adopts an auto-inhibited conformation where regulatory domains block 
access to the active site. l-phe-mediated allosteric activation induces a repositioning of the regulatory 
domains. Since a structure of activated wild-type hPAH is lacking, we addressed hPAH l-phe-mediated 
conformational changes and report the first solution structure of the allosterically activated state. Our 
solution structures obtained by small-angle X-ray scattering support a tetramer with distorted P222 
symmetry, where catalytic and oligomerisation domains form a core from which regulatory domains 
protrude, positioning themselves close to the active site entrance in the absence of l-phe. Binding of 
l-Phe induces a large movement and dimerisation of regulatory domains, exposing the active site. 
Activated hPAH is more resistant to proteolytic cleavage and thermal denaturation, suggesting that the 
association of regulatory domains stabilises hPAH.
The human phenylalanine hydroxylase (hPAH) catalyzes the hydroxylation of l-phenylalanine (l-Phe) into 
l-tyrosine (l-Tyr). The reaction is the first step in the catabolic pathway of l-Phe/l-Tyr and proceeds to feed neu-
rotransmitter biosynthetic pathways. In non-pathological conditions, degradation of excessive l-Phe by hPAH 
sustains physiological plasmatic levels of l-Phe (<120 µM)1. Deficiency in hPAH leads to phenylketonuria (PKU), 
characterised by a toxic accumulation of l-Phe and depletion of precursors for neurotransmitter biosynthesis 
in the central nervous system that overall result in cognitive disability and neurological impairment. Despite 
being the most prevalent disorder of the amino acid metabolism, the pathophysiology of PKU remains to be 
fully elucidated and treatment options are mostly limited to a life-long l-Phe-restricted diet1. PKU is caused by 
mutations in the PAH gene, most being missense mutations that affect folding, catalysis and/or regulation of the 
enzyme2,3. Understanding the structural and regulatory properties of hPAH is essential to outline pathophys-
iological mechanisms in PKU and delineate novel therapeutic strategies. However, the difficult manipulation 
of recombinant hPAH has thus far hindered its structural characterisation. hPAH is a member of the aromatic 
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amino acid hydroxylases family (AAAH), also including tyrosine hydroxylase (hTH) and tryptophan hydroxylase 
(hTPH). All three members assemble as functional homotetramers, each subunit consisting of an N-terminal 
regulatory domain, a central catalytic domain and a C-terminal oligomerisation domain4. They harbor a catalytic 
non-heme iron coordinated by histidine and carboxylate residues and three waters, and use dioxygen and tetrahy-
drobiopterin (BH4) as cosubstrates. Structural analyses of hPAH have relied on crystal structures of truncated 
forms of the enzyme lacking one or two domains5–12 and full-length bound to BH412, and on crystallographic and 
SAXS structures of the full-length rat homologue13–15. Phenylalanine hydroxylase assembles as a dimer of dimers 
through the C-terminal domain, forming a central four-helix bundle and a tetrameric core of catalytic domains. 
l-Phe binds to a pocket in the active site where the BH4 and the Fe3+ cofactors are nested. Regulatory domains 
are connected to the tetrameric core through a linker (Arg111-Thr117) and positioned above the catalytic domains, 
with the N-termini blocking the access to the active site. To regulate l-Phe blood levels, hPAH displays a complex 
net of mechanisms that involve transition between oligomeric states, conformational changes, substrate activa-
tion, cofactor inhibition and activation by phosphorylation (Ser16). Activation by l-Phe increases hPAH activity 
by ~3-fold16. Models for the activation mechanism have diverged on whether local or global motions occur upon 
l-Phe binding, and whether an allosteric binding site exists apart from the active binding site. The recognition of 
an auto-inhibited conformation led to the premise that activation would require the N-terminus to move away 
and release the active site entrance14. Further studies suggested that, rather than a simple displacement of the 
N-terminal portion, a large-scale conformational change would occur17–22. Jaffe and colleagues19 were the first to 
hypothesise dimerisation of regulatory domains upon l-Phe activation. Solution structural analyses of rat PAH 
confirmed distinct conformations for the inactive and l-Phe-activated enzymes and supported dimerisation of 
regulatory domains as the substrate activation mechanism13,15. Where regulatory l-Phe binds has been a matter 
of debate, with authors positing either a sole l-Phe-binding site at the catalytic pocket23 or an additional allosteric 
binding site11,14,17,21,24–29 at the regulatory/catalytic interface14,17,24 or at the regulatory dimer interface11,28. 
Dimerisation of individual hPAH regulatory domains is well-established25,26,29,30 and a recent crystal structure 
shows a symmetric homodimer with two l-Phe molecules bound at the dimer interface11. However, a structure of 
the activated hPAH is still lacking to confirm the behavior of regulatory domains in the context of the full-length 
wild-type protein. We have addressed l-Phe-mediated conformational changes of human phenylalanine hydrox-
ylase and report the first structure of the allosterically activated state of human PAH. Our low resolution solution 
structures determined by small-angle X-ray scattering disclose a conformational transition from the inactive state 
(that agrees with crystallographic observations) to an active state where regulatory domains associate above the 
four-helix bundle. These structures, herein combined with biophysical data obtained for resting and activated 
states, validate the model of l-Phe allosteric activation and elucidate the regulatory mechanism of hPAH.
Results
Production of functional recombinant full-length wild-type human PAH. The kinetic properties of 
N-terminally His6-tagged full-length tetrameric hPAH were analyzed by activity assays. hPAH activity was deter-
mined as a function of l-Phe concentration (Fig. 1A) and the data were fitted with a modified Hill equation account-
ing for substrate inhibition31, allowing to estimate the Vmax (4688 ± 120 nmol l-Tyr·min−1·mg−1), S0.5 (107 ± 6 µM), 
h (1.8 ± 0.1) and catalytic efficiency (Kcat/S0.5 = 3.01 µM−1·min−1). An activation ratio of 3.04 was calculated using the 
hPAH activities obtained from the pre-activated and non-activated assays (Supplementary Table 1).
The affinity of hPAH for l-Phe was also analyzed by surface plasmon resonance (SPR). As observed in the 
Inset to Fig. 1B, the steady-state RU appear to exhibit a slightly biphasic behavior, with the first phase being prop-
erly fitted up to 250 μM with an estimated steady-state affinity constant (KD) of 47 ± 8 μM. The experimental Rmax 
estimated for the first phase of l-Phe binding per hPAH monomer was 1.7 ± 0.5 times higher than the theoretical 
Rmax. Taking into account the RU at the maximal l-Phe concentration (1 mM), the ratio between experimental 
RU and theoretical Rmax is 1.9 ± 0.5, for a fully active immobilised surface. Moreover, the observed interaction 
is completely abolished in the presence of saturating concentrations of l-Phe (Supplementary Fig. S1), further 
validating the chip surface activity and excluding unspecific binding behavior of l-Phe to hPAH.
Low-resolution structure of full-length human hPAH. We collected SAXS data on full-length hPAH in 
both the absence (hPAHfree) and presence of 1 mM l-Phe (hPAHPhe) to characterise the conformational changes 
observed upon allosteric activation. Solutions of hPAH are typically inhomogeneous, with the protein adopting a 
number of oligomeric states and recombinant full-length hPAH forming large aggregates. Thus an online separa-
tion strategy was utilised with a size-exclusion chromatography column coupled to the SAXS set-up, facilitating 
isolation of the functional tetrameric form of hPAH for structural analysis. The observed elution profiles confirm 
the successful separation of oligomeric forms (Fig. 2).
The SAXS profiles (Fig. 3A) and parameters extracted (Table 1) from the SEC-SAXS measurements of hPAH 
show that a significant change in structure occurs following exposure to l-Phe. The computed molecular mass 
determined from the experimental data supports the presence of a tetrameric species for the major peaks in both 
the free and bound forms (theoretical molecular mass ≈223 kDa), and the linearity of the Guinier plots (Fig. 3B) 
for sRg < 1.1 provides confidence that the peak is not significantly contaminated by larger aggregates. Clear dif-
ferences in the scattering profiles of the two samples are observed, providing direct evidence of distinct hPAHfree 
and hPAHPhe conformations. The appearance of a minimum at s ~ 0.1 Å−1 for hPAHPhe suggests that occupancy 
of the ligand binding site by l-Phe drives the tetramer toward a more rigid and potentially more compact struc-
ture. Indeed, the real-space distance distribution functions P(r) show compaction of the hPAH structure in the 
presence of l-Phe (Fig. 3C). hPAHfree displays a bell-shaped function with an extended tail at large distances r, 
indicative of a structure composed of a compact core and additional extended regions. hPAHPhe displays a sym-
metric bell-shaped function without a significantly extended component, typical of a compact globular structure. 
In fact, the particle maximum distance, Dmax, is 24 Å shorter than that of the free protein. A reduction in the size 
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of hPAHPhe relative to hPAHfree is also supported by an observed ~4 Å decrease in the radius of gyration Rg, again 
indicating that hPAH becomes more compact when ligand-bound.
The Kratky plots of hPAHfree and hPAHPhe reveal folded proteins with non-significant flexibility, exhibiting 
parabolic peaks with maxima close to 1.1 at sRg = √3 and that converge to zero32 (Fig. 4A). However, at higher 
angles the Kratky profiles diverge, with a more gradual decay to zero in the absence of l-Phe. Whether this is 
a result of two distinct conformations or of an increased relative flexibility for hPAHfree can be assessed by the 
Porod-Debye plot. The Porod-Debye approximation describes the decay of the scattering intensity as s4·I(s) vs. 
s4 33. Folded particles, which have a clear scattering contrast, are predicted to display an asymptote at high s values. 
In flexible systems, the contrast between solvent and particle decreases and the asymptote is lost33. The clear and 
distinct plateaus of hPAHfree and hPAHPhe (Fig. 4B) exclude destabilisation of the enzyme and confirm the exist-
ence of two distinct conformational states.
Low resolution structure determination was performed and the ab initio shapes reconstructed from the exper-
imental data offer a hint about how domain rearrangement may occur in hPAH. A core of approximate dimen-
sions of 92 × 88 × 56 Å for hPAHfree and 114 × 88 × 48 Å for hPAHPhe easily accommodates a catalytic tetramer 
(determined as 100 × 78 × 42 Å from the hPAH118–452 crystal structure, PDB 2PAH10) (Supplementary Fig. S2). 
In both ab initio envelopes, peripheral volume can be occupied by the regulatory domains. These regions of scat-
tering density differ in their relative position to the core: in hPAHfree two to four regions extend along the major 
axis that corresponds to the plane formed by the catalytic tetramer (the largest dimension increasing to ~136 Å); 
in hPAHPhe two regions protrude along the minor axis, one above and one below the plane along the major axis 
(total height across the minor axis ~116 Å).
The overall shapes suggest a rearrangement of the regulatory domains upon allosteric activation by l-Phe. To 
determine the positions of regulatory domains in the absence and presence of l-Phe, we modeled the assembly 
of hPAH by rigid-body refinement. P222 symmetry restraints were applied to the tetramer. The high-resolution 
structures of the human regulatory, catalytic and oligomerisation domains were used for modeling, while miss-
ing regions (affinity tag, N-terminus and inter-domain linkers) were generated by CORAL and modeled as 
Figure 1. Kinetic characterisation of hPAH. Panel A, Effect of substrate concentration on the enzymatic activity 
of hPAH. Activity was measured at 25 °C in HEPES buffer pH 7.0 with 0.112 µM hPAH and 75 µM BH4. The 
obtained values for Vmax, S0.5, h, Kcat/S0.5 and activation ratio are summarised in Supplementary Table 1. Panel B, 
Binding of l-Phe to hPAH determined by surface plasmon resonance. Inset, effect of l-Phe concentration on the 
steady-state response units.
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dummy residues. A number of independent reconstructions were performed for each hPAH form and in each 
case the structures calculated are highly consistent (Fig. 5), revealing two distinct conformational states. Figure 6 
shows the two models that best fit the experimental data. The hPAHfree conformation in solution resembles that 
observed in the crystal structure of the rat protein (PDB 5DEN): separated regulatory domains are positioned 
above and below the plane of the catalytic tetramer. The N-terminal extensions (which include the affinity tag 
of our construct and the unstructured N-terminal tail of hPAH) protrude towards the solvent. The presence of 
l-Phe induces a repositioning of the regulatory domains, which adopt dimer-like structures above and below the 
four-helix bundle. The N-terminus is coiled around the regulatory domains.
Effect of l-Phe on the global conformation and thermal stability of hPAH. Biophysical method-
ologies were herein employed to analyze the effect of incubation of full-length hPAH with 1 mM l-Phe on the 
protein’s conformational stability. Far-UV circular dichroism (CD) spectra of hPAH (not shown) exhibited a min-
imum at 222 nm, characteristic of proteins with high α-helical content. Upon thermal unfolding monitored by 
CD at 222 nm, hPAH displays a two-phase transition (Fig. 7A) best fitted with two Tm values that are significantly 
upshifted in the presence of 1 mM l-Phe (Table 2). Thermal denaturation assays monitored by differential scan-
ning fluorimetry (DSF) yielded profiles which also displayed a two-phase transition (Fig. 7B) and were likewise 
best fitted with two Tm values that increase upon incubation with 1 mM l-Phe (Table 2). To analyze the global 
conformational changes of hPAH in the absence or presence of l-Phe, limited proteolysis by trypsin was analyzed 
as a function of time (Fig. 7C), allowing to estimate proteolytic rates (Table 2). Digestion of hPAH with trypsin 
leads to a progressive disappearance of the ≈56-kDa full-length band and concomitant formation of a ≈49-kDa 
band, as well as bands with lower molecular weights (Supplementary Fig. S3). As observed in Table 2, proteolytic 
rates indicate that the digestion of full-length hPAH is nearly 3 times slower in the presence of l-Phe as compared 
to the non-incubated protein. Intrinsic tryptophan fluorescence spectra were recorded for non-incubated and 1 
Figure 2. SEC-SAXS elution profiles of hPAHfree (non-incubated, panel A) and hPAHPhe (incubated with 1 mM 
l-Phe, panel B). Frames are plotted in respect to the elution time. The size-exclusion chromatography column 
coupled to the beam allowed separating the tetramer peak (marked with *) from higher-order aggregates. Insets 
represent the Rg values for each frame along the tetramer peak. The sample frames were manually selected from 
the region where the Rg is constant. Buffer frames were selected using the “Buffer Automatic Selection” function 
of CHROMIXS.
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mM l-Phe-incubated hPAH (Supplementary Fig. S4). The spectrum of non-incubated hPAH exhibits a broad 
band with λmax ≈ 330 nm, where as incubation with 1 mM l-Phe leads to a slight decrease in the band intensity 
accompanied by a red-shift in λmax to ≈340 nm.
Figure 3. SAXS analysis of hPAHfree (non-incubated; blue) and hPAHPhe (incubated with 1 mM l-Phe; red). 
Panel A, experimental scattering curves. A shift in the middle-s region suggests a structural difference between 
the free and Phe-bound protein consistent with domain rearrangement. Panel B, Guinier plots within the range 
of 0.50 < sRg < 1.02 for hPAHfree and 0.52 < sRg < 1.08 for hPAHPhe. Dots represent experimental points and 
lines represent linear regressions. No significant deviations from linearity are observed in the Guinier plot, 
thus no direct evidence of aggregation or polydispersity is observed. Panel C, pair-distribution functions P(r) 
derived from the scattering profiles. The P(r) function represents the sample in the real space. The differences 
in both curves suggest a conformational change upon addition of l-Phe: the loss of the extended tail at large 
r and the Dmax decrease indicate a transition between an elongated conformation in hPAHfree and a compact 
conformation in hPAHPhe.
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Discussion
The availability of structural data for full-length human phenylalanine hydroxylase has thus far been ham-
pered by the inability to produce a conformationally homogeneous tetrameric preparation. Indeed, Flydal et 
al. recently reported a crystallographic structure of the three domains of hPAH, which required a truncation of 
the N-terminal thirteen amino acids to obtain a homogeneous conformation within the crystals12. Herein we 
employed an N-terminal His6-tag with a short linker to obtain a preparation amenable for the structural charac-
terisation of full-length hPAH. In order to validate the structural data obtained in this work, a comparative analy-
sis of the functional and biophysical properties of the fusion protein and the untagged hPAH (literature data) was 
carried out. The obtained data show an identical behavior indicating that the His6-tag does not influence hPAH 
function and structure. hPAH assembles as a tetramer that displays the expected kinetic parameters in terms of 
catalytic efficiency and positive cooperativity, retaining its regulatory properties namely l-Phe activation16. The 





hPAHfree 43.5 ± 0.37 44.4 ± 0.17 147 336,000 210 223
hPAHPhe 40.1 ± 0.37 40.4 ± 0.13 123 367,000 229
Table 1. SAXS structural parameters of hPAHfree (non-incubated) and hPAHPhe (1 mM l-Phe). Radii of 
gyration (Rg) were estimated from the Guinier approximation and the pair-distribution function P(r). 
Maximum particle dimensions (Dmax) were obtained from the pair-distribution function. Excluded particle 
volumes (VP) were estimated from the Porod approximation. Molecular mass (MM) values were derived 
from the Porod volume as MM = VP/1.6. The expected molecular mass (MMexpected) was estimated based on 
the protein primary sequence. The experimental MMs are close to the expected and confirm the presence of 
tetrameric hPAH. The differences in Rg and Dmax between the free- and bound-protein suggest a conformational 
change that brings the protein to a more compact conformation in the presence of ligand.
Figure 4. Analysis of flexibility versus conformational changes. Panel A, dimensionless Kratky plots (blue, non-
incubated hPAH; red, l-Phe-incubated hPAH). Panel B, Porod-Debye plots limited by the s value corresponding 
to the major Kratky peak. Dots represent experimental data for hPAHfree (non-incubated; blue) and hPAHPhe 
(1 mM l-Phe; red). The parabolic peak of the Kratky function with a maximum of 1.1 at sRg = √3 and 
convergence to zero reveals folded proteins. The differences at high s between hPAHfree and hPAHPhe suggest a 
conformational change that is confirmed by the Porod-Debye plot that shows two discrete plateaus.
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thermal denaturation profile displays the characteristic two-phase transitions previously determined by differ-
ential scanning calorimetry and Far-UV CD23, characterised by a lower Tm1 of 46 °C and a higher Tm2 of 54 °C. 
These transitions have been attributed to the denaturation of regulatory and catalytic domains, respectively23. 
In accordance with these studies, hPAH is stabilised in the presence of 1 mM l-Phe, resulting in a shift of both 
transitions to higher temperatures.
The model of hPAH allosteric activation by l-Phe has been controversial on whether a local rearrangement 
around the catalytic site or a large-scale conformational change takes place. Studies supporting the latter model 
suggest that, similarly to rat PAH, activation of the hPAH involves repositioning and dimerisation of regula-
tory domains11,13,15,19,29,30,34. However, the lack of a structure of full-length activated human PAH has hampered 
Figure 5. Evaluation of rigid-body modeling of hPAHfree (non-incubated; panel A) and hPAHPhe (1 mM l-Phe; 
panel B). For each sample, five reconstructions were performed and superimposed to check for consistency 
of the models. In all models, tetramer cores (catalytic and oligomerisaton domains) are represented in gray. 
Regulatory domains are shown in a different color for each reconstruction. The chi-square of each model 
is displayed in its corresponding color. Dots represent the reconstruction of the N-terminus for the most 
representative model. The obtained structures from multiple rigid body refinements show identical position of 
domains, indicating reliability of the models.
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validation of this model. Using small-angle X-ray scattering, we determined the low-resolution structures of 
the inactive (hPAHfree) and active (hPAHPhe) states of full-length hPAH. Our structures validate the model of 
allosteric activation: that a large-scale movement and dimerisation of regulatory domains follows the cooperative 
binding of l-Phe.
The differences in scattering profiles and the distinct Porod-Debye plateaus for hPAHfree and hPAHPhe confirm 
the existence of two discrete conformational states. Similar variations in the 0.05–0.2 Å−1 region have previously 
been observed for rat PAH13,15. For the rat enzyme, where crystal structures of the inactive state are available, 
these variations were attributed to a conformational transition: SAXS and crystallographic data agreed upon the 
free-protein conformation, while a mismatch was observed when the crystal structures were compared with the 
Figure 6. SAXS models of hPAHfree (non-incubated; panel A) and hPAHPhe (1 mM l-Phe; panel B). 
Reconstruction was based on the coordinates of hPAH regulatory domain (PDB 5FII) and hPAH catalytic/
oligomerisation domains (PDB 2PAH), using P222 symmetry. The models are shown in surface mode in two 
orientations, the bottom view being rotated 90° around the horizontal axis. Each color represents a monomer 
(regulatory domains are shown in darker tones). The scattering curves below each model (panel C, non-
incubated hPAH; panel D, l-Phe-incubated hPAH) show the fit between experimental data (black line) and 
the corresponding model (red line). While the assembly of tetramer core is not altered by 1 mM l-Phe, the 
regulatory domains show a large-scale movement to form a dimeric structure above the four-helix bundle. This 
rearrangement explains the structural differences observed in the scattering profile of both hPAH states.
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SAXS profile of the l-Phe-activated protein13,15. hPAH experiences a significant decrease in both Rg and Dmax 
upon l-Phe binding, suggesting compaction of the protein. This is consistent with an l-Phe-specific change 
in the relative positions of hPAH domains. This compaction contrasts with the minor increase in Rg (40 Å to 
41 Å) and the unchanged Dmax (117 Å) observed for activated rat PAH13,15. The dimensions of rat PAH (both free 
and l-Phe-bound) are close to those of hPAHPhe, while hPAHfree dimensions suggest a more extended particle. 
These findings may result from differences inherent to the human and rat proteins, mainly due to the sequence 
Figure 7. Response of hPAHfree (non-incubated; blue) and hPAHPhe (1 mM l-Phe; red) to thermal denaturation 
and tryptic digestion. Panel A, thermal unfolding profile of hPAH as determined by far-UV CD. Each data 
point represents the mean of two independent assays and error bars represent the standard error. Panel B, 
thermal denaturation profiles of hPAH as determined by DSF. Both far-UV CD and DSF show two transitions 
that correspond to denaturation of the regulatory (first midpoint; Tm1) and catalytic (second midpoint; Tm2) 
domains. 1 mM l-Phe stabilises hPAH, resulting in an increase of both Tm values. Panel C, degradation of 
full-length hPAH by trypsin as a function of time. In each time point, the percentage of remaining full-length 
protein is normalised with respect to time 0 min. Each data point represents the mean of independent assays 
and error bars represent the standard error, where n = 4 for hPAHfree and n = 3 for hPAHPhe. The free enzyme 
is more susceptible to fast digestion. Conformational changes induced by l-Phe make hPAH more resistant to 
trypsin. The obtained melting temperatures (Tm) and proteolytic rates (kobs) are summarised in Table 2.
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divergence of their regulatory domain (that probably reflects in the observed differences in the response to l-Phe 
activation). Indeed, a comparative analysis of rat and human PAH by molecular dynamics simulations revealed 
a higher degree of flexibility for the human free protein, particularly in regulatory domains and C-terminal hel-
ices12. This flexibility may account for the occurrence of less compact conformations for hPAHfree. Alternatively, 
the differences between SAXS parameters of rat and human PAH may arise from the N-terminus arrangement 
following repositioning of regulatory domains.
The overall assembly of the tetrameric core in our models is similar to the crystal structures of rat and human 
PAH (Supplementary Fig. S5): the C-terminal helices assemble in a four-helix bundle, forming a tetramer of cat-
alytic domains. In the hPAH crystal structure, the tetramer is formed by a dimer of dimers through the two-fold 
crystallographic symmetry. The crystal structure of hPAH revealed that, within the dimer, a backbone variation 
in the region connecting the catalytic and oligomerisation domains results in a deviation from P222 symmetry10. 
This distortion was also observed in rat PAH: crystal structures (PDB codes 5DEN13, 5EGQ, 5FGJ15) revealed 
multiple conformations of the C-terminal helices, while a SAXS study suggested an even more pronounced asym-
metry in solution15. Our initial attempts of modeling hPAH with rigid P222 symmetry yielded the expected 
tetrameric assembly, with minimal discrepancy to the experimental data, but with steric clashes at the C-terminal 
helices. By orienting the helices into a distorted configuration similar to the crystallographic observations, we 
were able to generate a model without structural artifacts. The flexibility of the C-terminal has been suggested 
to determine the existence of several conformational states, where variations in the helices’ positions allow for 
repositioning of domains during allosteric activation and catalysis10,15,35.
Apart from the presence of a 14-residue inter-domain linker, we did not impose upon CORAL any confor-
mational restrictions for positioning the regulatory domains. Hence, their orientation in hPAHfree and hPAHPhe 
differs between multiple reconstructions and from that observed for the rat L-Phe-free protein or the human 
dimerised regulatory domain (PDB 5FFI11) structures. Despite the uncertainty of the regulatory domains’ orien-
tation, their relative position in the tetramer is consistent and unveils a transition from the inactive conformation 
(seen in rat PAH crystal structures) to a dimeric configuration of regulatory domains. It has been suggested that 
the N-terminal auto-inhibitory peptide may move away from the active site entrance upon rearrangement of the 
regulatory domains. However, this cannot be assessed from the current data and low-resolution models.
The transition from hPAHfree to hPAHPhe explains some of the aforementioned biophysical observations. 
The differences between the SPR theoretical and experimental Rmax had been previously observed by Stokka 
and Flatmark18,22. The authors proposed that a conformational transition, more than a ligand-binding event, 
would contribute to the obtained response for hPAH/l-Phe interactions. Knappskog and colleagues attributed 
the l-Phe-induced 10 nm red-shift on the emission maximum of hPAH to a change in Trp120 environment20. 
Structure analysis reveal that Trp120, located in the inter-domain linker, becomes more solvent exposed upon 
repositioning and dimerisation of the regulatory domains. This conformational transition also results in differen-
tial susceptibility to proteolysis. Two stages of cleavage can be observed: a fast initial cleavage, which results in a 
large fragment, and a subsequent slow cleavage, which yields a smaller fragment. Immunoblotting with anti-His 
antibody revealed that initial cleavage removes the N-terminal portion of full-length hPAH (not shown). In the 
presence of l-Phe, hPAH is more resistant to this stage, suggesting that association of regulatory domains protects 
against fast tryptic digestion probably by decreasing the accessibility of the hinge connecting the regulatory and 
catalytic domains (Arg111-Thr117: RDKKKDT) to trypsin digestion.
The low-resolution structure of a full-length hTH isoform (hTH1), one of the members of the AAAH family, 
was recently determined by SAXS36. hTH1 displays a similar assembly as hPAHPhe: catalytic and oligomerisa-
tion domains assembled in P222 symmetry form the tetrameric core, while regulatory domains form a dimer 
above the four-helix bundle. Just as for PAH, the dimeric configuration of regulatory domains in hTH1 produces 
a similar secondary maximum in the mid-s region of the scattering curve. Despite the near-identical overall 
structure, slight differences in dimensions reveal a more compact structure for hPAH than hTH1 (Rg = 47.4 Å; 
Dmax = 200 Å). This is most likely explained as a difference in the flexibility of the C-terminal helices or the 
N-terminal peptide (twice as long in hTH1). Structural variations may also reflect different regulatory mecha-
nisms of hPAH and hTH1, which is not pre-activated by its substrate but is physiologically inhibited by catecho-
lamine derivatives. In opposition to hPAH, hTH1 regulatory domains dimerise both in the absence or presence 
of substrate37 and the scattering profile is identical in the absence and presence of inhibitor36. Although a confor-
mational change is expected to block/release the active site entrance, local changes of the N-terminal peptide are 
predicted rather than a global motion of the regulatory domains as observed for hPAH.
Methodology hPAHfree hPAHPhe
Far-UV CD Tm1: 46.0 ± 1.9 °CTm2: 57.5 ± 0.8 °C
Tm1: 55.0 ± 0.4 °C
Tm2: 62.6 ± 0.3 °C
DSF Tm1: 46.6 ± 0.2 °CTm2: 52.8 ± 0.1 °C
Tm1: 50.4 ± 0.2 °C
Tm2: 56.5 ± 0.1 °C
Limited proteolysis kobs = 0.33 ± 0.03 min−1 kobs = 0.12 ± 0.01 min−1
Table 2. Effect of l-Phe on the thermal and proteolytic stability of hPAH. Melting temperatures (Tm) were 
determined by far-UV CD and DSF. Proteolytic rates (kobs) were obtained from trypsin limited proteolysis. 
Thermal stability is increased in the presence of 1 mM l-Phe. Resistance to proteolytic digestion is also 
increased by l-Phe.
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Methods
hPAH expression and purification. Recombinant full-length human PAH was expressed as a hexa-histi-
dine (His6) fusion protein with an N-terminal His6 tag and a 26-amino acid linker in Escherichia coli Top10 cells 
transformed with the pTrcHis-hPAH plasmid as described in38. Bacteria were grown in Luria-Bertani broth sup-
plemented with 50 µg·mL−1 ampicillin at 37 °C. When OD600 reached 0.5, expression was induced by the addition 
of 1 mM isopropylthio-β-D-galactoside. Simultaneously, 0.2 mM ferrous ammonium sulfate (Fe2+) was added to 
the culture. After 3 h, at 37 °C, cells were harvested, resuspended in lysis buffer (50 mM sodium phosphate pH 7.8, 
300 mM NaCl, 10% glycerol) supplemented with 1 mM phenylmethylsulfonyl fluoride, DNaseI and 1 mg·mL−1 
lysozyme, and disrupted by three cycles of sonication during 60 sec at 50% duty free cycle (Media Cybernetics). 
After centrifugation at 13,000 g, 40 min, 4 °C, the soluble fraction was recovered for purification. An initial puri-
fication step was performed by immobilised metal affinity chromatography using a Ni-NTA resin (Qiagen) at 
4 °C. The cell lysates were added to the resin pre-equilibrated in lysis buffer supplemented with 10 mM imidazole 
and stirred for 1 h at 4 °C. The resin was applied onto the column and washed in lysis buffer with a 20 to 75 mM 
imidazole gradient and hPAH was eluted with 250 mM imidazole. hPAH was further purified by size-exclusion 
chromatography using a HiLoad Superdex 200 HR column (GE Healthcare) in 20 mM Hepes pH 7.0, 200 mM 
NaCl (SEC buffer), at 4 °C. Protein batches were stored in liquid nitrogen. The isolated pure tetrameric form 
was employed in all biochemical and biophysical methods. Alternatively, for the SEC-SAXS measurements, the 
protein eluted from the Ni-NTA column and containing pure hPAH in its multiple oligomeric states was washed 
in a PD-10 column with SEC buffer to remove imidazole and applied directly onto the beamline SEC column.
enzymatic activity assays. Enzymatic activity was measured in 100 mM Hepes pH 7.0 in a final reaction 
volume of 200 µL essentially as described in39. The reaction mix was prepared with 5 µg His6-hPAH (correspond-
ing to 0.112 µM of tetramer), 1 mM l-Phe (pre-activated condition) and 0.1 mg·mL−1 catalase and incubated 
for 4 min at 25 °C. Ferrous (Fe2+) ammonium sulfate (100 µM) was added and incubated for 1 min at 25 °C. The 
reaction was initiated by addition of 75 µM tetrahydrobiopterin (BH4). For determination of non-activated hPAH 
activity, the substrate l-Phe (1 mM) was added simultaneously with BH4. After 1 min, the reaction was stopped by 
adding 200 µL of cold 2% (v/v) acetic acid/ethanol solution, and the amount of produced l-Tyr was quantified by 
HPLC with fluorescence detection as in39. Specific activity is expressed in nmol of l-Tyr produced during 1 min 
per mg of protein (nmol l-Tyr·min−1·mg−1). The kinetic parameters were determined for the non-activated con-
dition using variable concentrations of l-Phe (0–4 mM).
Surface plasmon resonance. Binding of l-Phe to hPAH was evaluated by surface plasmon resonance 
(SPR) using a Biacore 4000 (GE Healthcare) instrument. The surface of a CM5 sensor chip was activated with 
400 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and 100 mM l-hydroxysuccinimide for 10 min. 
hPAH (10 µg·mL−1 in 10 mM sodium acetate pH 5.5) was immobilised onto the activated chip using the stand-
ard amine coupling procedure. hPAH was coupled to the surface with a 1 to 2 min injection time at a flow rate 
of 10 µL·min−1 in order to reach 2,000 to 5,000 response units (RU). The free surface was blocked with a 7 min 
injection of 1 M ethanolamine (pH 8.5). l-Phe was directly dissolved in running buffer (10 mM Hepes pH 7.2, 
150 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 0.05% (v/v) Tween-20, 1 mM DTT) and injected at 10 different 
concentrations using a 2-fold dilution series, with the highest concentration tested being 1000 µM. Interaction 
analysis cycles consisted of a 140 s sample injection (30 µL·min−1; association phase) followed by 240 s of buffer 
flow (dissociation phase). All sensorgrams were processed by first subtracting the binding response recorded 
from the control surface (reference spot), followed by subtracting of the buffer blank injection from the reaction 
spot. All assays were performed at 25 °C. The interaction was assessed from the steady-state binding levels against 
l-Phe concentration, using the provided Biacore 4000 evaluation software (GE Healthcare).
Small-angle X-ray scattering. Size-exclusion chromatography-coupled SAXS (SEC-SAXS) data were 
collected at B21 beamline at Diamond Light Source (Supplementary Table 2). hPAH samples (at 12 mg·mL−1; 
≈214 µM in monomer) were injected in a Shodex KW-404 column using SEC buffer (equilibration and elu-
tion) at a flow-rate of 0.16 mL·min−1. For hPAHPhe SAXS measurements, hPAH was pre-incubated with 1 mM 
l-Phe, which was also present in the SEC elution buffer. The estimated average tetramer concentration in the 
elution profile (Fig. 2B) is ≈15 µM, which implies ≈96% hPAH enzyme occupancy at this l-Phe concentration. 
Measurements were performed at 20 °C. Data were recorded using a Pilatus 2 M detector covering a range of 
momentum transfer 0.004 Å−1 ≤ s ≥ 0.408 Å−1 (s = 4πsinθ/λ, where 2θ is the scattering angle, and λ = 1.0 Å is 
the X-ray wavelength). Data were analyzed using the ATSAS program suite40. SEC-SAXS data were plotted with 
CHROMIXS41 and the sample frames were selected from the peak region where the radius of gyration (Rg) is 
not influenced by aggregates. The final curves were generated after buffer subtraction (grey boxes in Fig. 2A,B). 
The radius of gyration (Rg) was estimated from the Guinier approximation using PRIMUS42, and the maximum 
particle dimension (Dmax) from the pair distribution function P(r) using the GNOM package43. The molecular 
mass was estimated from the Porod volume. Ab initio shape determination was performed with DAMMIN44, 
DAMCLUST45 and the DAMAVER suite46: 20–30 dummy atom models were generated, clustered, aligned, aver-
aged and refined to obtain the final model. Rigid body modeling was performed with CORAL45 using the struc-
ture coordinates of human catalytic/oligomerisation domain (PDB 2PAH) and human regulatory domain (PDB 
5FII) as starting models. P222 symmetry was imposed for structure determination. The final structures were fit 
to the experimental data using CRYSOL47.
Differential scanning fluorimetry. Thermal denaturation curves of hPAH were obtained by differential 
scanning fluorimetry (DSF). The reaction mix was prepared with 100 µg·mL−1 hPAH (corresponding to 0.45 µM 
of tetramer) and 2.5× Sypro Orange (Invitrogen; 5,000× commercially available stock solution). Thermal stability 
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was measured between 20–90 °C with temperature increments of 1 °C·min−1. Fluorescence data were acquired 
in the FRET channel using a C1000 Touch thermal cycler equipped with a CFX96 optical reaction module (Bio 
Rad). Data were processed using CFX Manager Software V3.0 (Bio-Rad) and GraphPad Prism 6. The curves were 
fitted to a biphasic dose-response function and the melting temperatures of the regulatory (Tm1) and catalytic 
(Tm2) domains were obtained from the midpoint of the two transitions.
Far-UV circular dichroism spectropolarimetry. Far-UV circular dichroism (Far-UV CD) spectra and 
thermal denaturation profiles were recorded in a Jasco J-710 spectropolarimeter, coupled to a Jasco PTC-348WI 
Peltier temperature controller and a Haake G/D8 water bath. Spectra of hPAH (at 250 μg·mL−1) in SEC buffer 
were measured in a 0.2 cm light path cuvette, and resulted from two accumulations at a scan rate of 50 nm·min−1, 
and a nitrogen flow of 6 L·min−1. Thermal denaturation profiles were obtained in the 10–90 °C temperature 
range, with a 1 °C·min−1 slope, and monitored at 222 nm (data pitch: 1 °C; delay time: 0 s; N2 flow: 3.5 L·min−1). 
Experimental data from thermal denaturation curves were fitted with a biphasic dose-response function and the 
Tm values were obtained from the midpoint of the first and second transitions.
intrinsic tryptophan fluorescence. Intrinsic tryptophan fluorescence (ITF) emission spectra were 
recorded in a Hitachi F-2000 spectrofluorimeter at 25 °C using λexc = 295 nm (slit 10 nm), λem between 305 and 
500 nm (slit 10 nm) and a scan speed of 240 nm·min−1. Samples contained 20 μg·mL−1 of protein (final concentra-
tion) to maintain A295 < 0.02. The l-Phe effect was monitored by incubating the protein samples with 1 mM l-Phe 
for 5 min, at 25 °C, prior to ITF analysis.
Limited proteolysis by trypsin. Limited proteolysis was performed at 25 °C in SEC buffer, using a 
trypsin:hPAH mass ratio of 1:200. Before cleavage, hPAH was incubated in the absence or presence of 1 mM 
l-Phe for 10 min at 25 °C. The reaction was initiated by addition of trypsin. At each time point, an aliquot was 
collected and the reaction stopped by addition of soybean trypsin inhibitor (at a trypsin:inhibitor mass ratio 
of 1:1.5) and 4× denaturing loading buffer. Samples were denatured for 5 min at 95 °C. The proteolytic profile 
was visualised by SDS-PAGE using 10% Bis-Tris precast gels (Invitrogen) ran with buffer 50 mM MOPS pH 7.7, 
50 mM Tris, 0.1% SDS, 1 mM EDTA at 200 V. Gel bands were quantified with ImageJ and data were fitted to a 
single exponential decay equation using GraphPad Prism 6.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
authors on reasonable request.
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